After years of limited progress in the treatment of advanced non‐small cell lung cancer (NSCLC), a major leap forward has been made with the introduction of programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) targeting immune checkpoint inhibitors. This evidence concerns the gene PDCD1 and lung cancer.